3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
13
Active not recruiting
10
Completed
3
Terminated
2
Enrolling by invitation
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Gastrointestinal
2
Endocrine
2
Conditions
Carcinoma, Non-Small-Cell Lung
129
Breast Neoplasms
113
Neoplasms
97
Neoplasm Metastasis
78
Melanoma
73
Leukemia, Myeloid, Acute
69
Colorectal Neoplasms
69
Prostatic Neoplasms
60
Multiple Myeloma
52
Lung Neoplasms
52
Ovarian Neoplasms
51
Squamous Cell Carcinoma of Head and Neck
46
Triple Negative Breast Neoplasms
42
Recurrence
41
Carcinoma, Renal Cell
39
Carcinoma, Hepatocellular
39
Pancreatic Neoplasms
36
Myelodysplastic Syndromes
36
Glioblastoma
35
Brain Neoplasms
34
Lymphoma
31
Stomach Neoplasms
30
Lymphoma, Non-Hodgkin
30
Endometrial Neoplasms
30
Leukemia
29
Lymphoma, Large B-Cell, Diffuse
28
Head and Neck Neoplasms
28
Uterine Cervical Neoplasms
26
Cholangiocarcinoma
26
Urinary Bladder Neoplasms
24
Interventions
lutetium Lu 177 dotatate
1
lanreotide
1
Octreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Gastro-enteropancreatic neuroendocrine tumor
×
1 year
×
Clear all
NCT05987176
2026-01-14
NELMAS
Imperial College London
Phase 2
Terminated
1 enrolled
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled